Grace Therapeutics, Stock Z Score

GRCE Stock   3.28  0.05  1.55%   
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Grace Therapeutics, Piotroski F Score and Grace Therapeutics, Valuation analysis.
For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.
  
At present, Grace Therapeutics,'s Net Working Capital is projected to decrease significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 13.4 M, whereas Net Invested Capital is forecasted to decline to about 58.7 M. At present, Grace Therapeutics,'s Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 6.7 M, whereas Selling General Administrative is forecasted to decline to about 6.3 M.

Grace Therapeutics, Company Z Score Analysis

Grace Therapeutics,'s Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

 = 

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

 = 

1.2 * (

Working Capital

/

Total Assets )

Second Factor

 = 

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

 = 

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

 = 

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

 = 

0.99 * (

Revenue

/

Total Assets )

Grace Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Grace Therapeutics, is extremely important. It helps to project a fair market value of Grace Stock properly, considering its historical fundamentals such as Z Score. Since Grace Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Grace Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Grace Therapeutics,'s interrelated accounts and indicators.
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition

According to the company's disclosures, Grace Therapeutics, has a Z Score of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The z score for all United States stocks is 100.0% higher than that of the company.

Did you try this?

Run FinTech Suite Now

   

FinTech Suite

Use AI to screen and filter profitable investment opportunities
All  Next Launch Module

Grace Fundamentals

About Grace Therapeutics, Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Grace Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Grace Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Grace Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Grace Therapeutics, is a strong investment it is important to analyze Grace Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Grace Therapeutics,'s future performance. For an informed investment choice regarding Grace Stock, refer to the following important reports:
Check out Grace Therapeutics, Piotroski F Score and Grace Therapeutics, Valuation analysis.
For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grace Therapeutics,. If investors know Grace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grace Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Grace Therapeutics, is measured differently than its book value, which is the value of Grace that is recorded on the company's balance sheet. Investors also form their own opinion of Grace Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Grace Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grace Therapeutics,'s market value can be influenced by many factors that don't directly affect Grace Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grace Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grace Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.